Back

Subgroup-Specific Associations of GRIA Genes Encoding AMPA Glutamate Receptor Subunits with Patient Survival in Medulloblastoma

Saciloto, B.; Dalmolin, M.; Roesler, I. B. S.; Ribas Filho, J. M.; Malafaia, O.; Fernandes, M. A. C.; Thomaz, A.; Roesler, R.; Isolan, G. R.

2026-02-26 cancer biology
10.64898/2026.02.24.707769 bioRxiv
Show abstract

Brain cancers hijack biological systems involved in neural development and synaptic plasticity. Medulloblastoma (MB), the most common malignant brain tumor in children, is thought to arise from disruptions in neurodevelopmental programs. Glutamatergic transmission mediated by -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (AMPARs) has been implicated in synaptic communication between adult brain tumors and surrounding neurons; however, the possible role of AMPARs in MB remains largely unexplored. Here, we analyzed the expression of genes encoding AMPAR subunits, GRIA1-4, in datasets of MB tumors, revealing distinct expression patterns and subgroup-specific associations with overall survival (OS) across molecular subgroups and histological variants. Expression of GRIA1, GRIA3, and GRIA4 was significantly lower in MB in comparison with normal cerebellar tissue. Higher GRIA1, GRIA2, and GRIA4 transcription was associated with more favorable patient outcomes in specific MB subgroups. In contrast, high expression of GRIA3 in SHH, or of either GRIA3 or GRIA4 in Group 3 MB, was associated with worse prognosis. Particularly robust but opposing associations with patient survival were found for GRIA3 and GRIA4 in SHH MB. Analysis of GRIA mRNA levels in MB cell lines representing different molecular subgroups, using data from The Human Protein Atlas, showed partial concordance with expression patterns observed in tumors. Together, these findings suggest that GRIA genes and their corresponding AMPAR subunits may have subgroup-specific prognostic relevance in MB and merit further investigation.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Neuro-Oncology
30 papers in training set
Top 0.1%
39.7%
2
Acta Neuropathologica Communications
81 papers in training set
Top 0.1%
6.4%
3
Neuro-Oncology Advances
24 papers in training set
Top 0.1%
4.2%
50% of probability mass above
4
Brain
154 papers in training set
Top 2%
3.7%
5
Scientific Reports
3102 papers in training set
Top 41%
3.1%
6
Acta Neuropathologica
51 papers in training set
Top 0.4%
2.8%
7
Oncogene
76 papers in training set
Top 0.7%
2.6%
8
Neoplasia
22 papers in training set
Top 0.1%
2.6%
9
Cell Reports
1338 papers in training set
Top 20%
2.1%
10
Cell Death & Disease
126 papers in training set
Top 0.6%
2.1%
11
Nature Communications
4913 papers in training set
Top 51%
1.7%
12
eLife
5422 papers in training set
Top 47%
1.3%
13
Cancers
200 papers in training set
Top 4%
1.2%
14
Molecular Oncology
50 papers in training set
Top 0.6%
1.2%
15
Cell Reports Medicine
140 papers in training set
Top 6%
1.1%
16
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 39%
1.1%
17
Cancer Research
116 papers in training set
Top 3%
1.0%
18
International Journal of Cancer
42 papers in training set
Top 1%
0.9%
19
Cancer Cell
38 papers in training set
Top 1%
0.9%
20
Genome Medicine
154 papers in training set
Top 7%
0.9%
21
Cells
232 papers in training set
Top 6%
0.8%
22
PLOS ONE
4510 papers in training set
Top 66%
0.8%
23
Clinical Epigenetics
53 papers in training set
Top 0.9%
0.8%
24
Frontiers in Oncology
95 papers in training set
Top 3%
0.8%
25
Molecular Cancer
14 papers in training set
Top 1.0%
0.8%
26
Communications Biology
886 papers in training set
Top 29%
0.6%
27
Neurobiology of Disease
134 papers in training set
Top 5%
0.6%